(R)-4-formyl-1,3-thiazolidine-3-carboxylic acid tert-butyl ester | 162204-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (R)-4-formyl-1,3-thiazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: (R)-tert-butyl 4-formylthiazolidine-3-carboxylate；N-Boc-L-thiazolidine-4-carbaldehyde；N-tert-butoxycarbonyl-(R)-(-)thiazolidine-4-carboxaldehyde；(4R)-3-t-butoxycarbonyl-4-formylthiazolidine；tert-butyl (4R)-4-formyl-1,3-thiazolidine-3-carboxylate
• CAS: 162204-13-9
• 化学式: C₉H₁₅NO₃S
• 分子量: 217.289
• InChiKey: USCSKAAEPJVLMA-SSDOTTSWSA-N

物化性质

• 沸点：
  321.1±42.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  71.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-4-formyl-1,3-thiazolidine-3-carboxylic acid tert-butyl ester 在 sodium tetrahydroborate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  具有草硫氮平环的（-）-大黄连素的全合成。第1部分。草硫氮平环系统的形成

  摘要：

  研究了eudistomins 1中草硫氮杂pine环的形成。噻唑烷基-β-咔啉5已成功转化为噻吲哚并喹唑烷7，但尝试将7氧化为1却没有成功。氧化性环化NCS取代1-取代-2羟基-β-咔啉24或相应的酸催化环化反应小号氧化物 26用TsOH给草硫氮平 25，其容易地转化为（+）-十溴联苯二胺L（+）- 1f。（-）-Debromoeudistomin L（-）- 1f由N-羟基色胺11和D-半胱氨酸30制备。

  DOI：

  10.1039/b004570p
• 作为产物：
  描述：

  N-Boc-(R)-噻唑-4-羧酸 在 lithium aluminium tetrahydride 、 TEA 、 2-氯-1-甲基吡啶碘化物 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (R)-4-formyl-1,3-thiazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Stereoselective synthesis of β-hydroxy-α-amino acids β-substituted with non-aromatic heterocycles

  摘要：

  We have stereo selectively synthesised P-hydroxy-a-amino acids beta-substituted with non-aromatic heterocycles by means of a condensation reaction between enantiomerically pure heterocyclic aldehydes and the (R)-(+)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (Schollkopf's reagent) as a chiral auxiliary. The stereocontrolled addition gave mixtures of diastereoisomers whose steric configurations were assigned on the basis of spectroscopic data and X-ray analysis. Upon controlled hydrolysis, the adducts were transformed into the corresponding methyl esters of beta-hydroxy-beta-heterocyclic substituted a-amino acids. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2007.05.040

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US06310095B1

  公开（公告）日：2001-10-30

  Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下结构式或其药用可接受盐的化合物，其中R1为(a)氢，(b)较低烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，和(i)杂环-L2—；R2选自(a) (b) —C(O)NH—CH(R14)—C(O)OR15，(d) —C(O)NH—CH(R14)—C(O)NHSO2R16，(e) —C(O)NH—CH(R14)-四唑基，(f) —C(O)NH-杂环，和(g) —C(O)NH—CH(R14)—C(O)NR17R18；R3为取代或未取代的杂环或芳基，取代或未取代的环烷基或环烯基，以及—P(W)RR3RR3′；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环，或(杂环)烷基；L1为空缺或选自(a) —L4—N(R5)—L5—，(b) —L4—O—L5—，(c) —L4—S(O)n—L5—，(d) —L4—L6—C(W)—N(R5)—L5—，(e) —L4—L6—S(O)m—N(R5)—L5—，(f) —L4—N(R5)—C(W)—L7—L5—，(g) —L4—N(R5)—S(O)p—L7—L5—，(h)可选择取代的烷基，(i)可选择取代的烯基，(j)可选择取代的炔基，(k)共价键，(l)和(m)是蛋白异戊二烯基转移酶的抑制剂。还公开了蛋白异戊二烯基转移酶抑制剂组合物和抑制蛋白异戊二烯基转移酶的方法。
• Amino acid derivatives
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20030013725A1

  公开（公告）日：2003-01-16

  A compound of the formula (1): 1 [wherein R 1 is (substituted) alkyl, alkoxy, phenyl, hetero ring etc.; A is bond, CO, SO 2 ; R 2 is H, (substituted) alkyl etc.; D is alkylene etc.; E is COO, OCO, O, S, SO, SO 2 etc.; R 3 is (substituted) alkyl, carbocyclic ring, hetero ring; J is O, NR 16 (R 16 is H, substituted alkyl); R 4 is (substituted) alkyl, carbocyclic ring, hetero ring.] or non-toxic salt thereof, and an N-type calcium channel blocker comprising it as an active ingredient. The compounds of the formula (I) possess an inhibitory action on N-type calcium channel, so they are useful as agent for the prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis or epilepsy etc. or agent for the treatment of pain.

  化合物的式子（1）：1[其中R1是（取代）烷基，烷氧基，苯基，杂环等；A是键，CO，SO2；R2是H，（取代）烷基等；D是烷基等；E是COO，OCO，O，S，SO，SO2等；R3是（取代）烷基，环烷基，杂环；J是O，NR16（R16是H，取代烷基）；R4是（取代）烷基，环烷基，杂环。或其非毒性盐，以及作为活性成分的N型钙通道阻滞剂。式（I）的化合物具有对N型钙通道的抑制作用，因此它们可用作预防和/或治疗脑梗死、短暂性脑缺血发作、心脏手术后脑脊髓病、脊髓血管病、应激性高血压、神经症或癫痫等的药物或治疗疼痛的药物。
• Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20030232806A1

  公开（公告）日：2003-12-18

  The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification). 1 The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain

  本发明涉及化合物(I)及其盐（其中所有符号的含义与说明书中描述的相同）。化合物(I)具有N型钙通道的抑制活性，因此它们可用作预防和/或治疗脑梗死、短暂性脑缺血发作、心脏手术后脑脊髓病、脊髓血管病、应激性高血压、神经症、癫痫、哮喘和尿频等疾病的药物，或用作治疗疼痛的药剂。
• Antithrombotic Diamides
  申请人：Franciskovich Jeffry Bernard

  公开号：US20090062271A1

  公开（公告）日：2009-03-05

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本申请涉及公式I化合物（或其药学上可接受的盐），其制药组合物，以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。
• DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME
  申请人：CELLTRION, INC.

  公开号：US20150225455A1

  公开（公告）日：2015-08-13

  The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.

  本发明提供了一种具有优异的抗癌活性的多拉斯他汀-10衍生物，以及其制备方法和包含其作为活性成分的抗癌药物组合物。